Molecular structure of rofecoxib
Find information on thousands of medical conditions and prescription drugs.

Vioxx

Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was used in the treatment of osteoarthritis, acute pain conditions, and dysmenorrhoea. Formerly marketed by Merck & Co. under the trade names Vioxx, Ceoxx and Ceeoxx, it was voluntarily withdrawn from the market in 2004 because of concerns about increased risk of heart attack and stroke. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. Worldwide, over two million people were prescribed Vioxx at the time. In the year before withdrawal, Merck had a sales revenue of US$2.5 billion from Vioxx.

Rofecoxib was available on prescription as tablets and as an oral suspension.

COX-2 selective inhibitor

Rofecoxib belongs to the group of NSAIDs known as COX-2 selective inhibitors or coxibs (CycloOXygenase-2 InhiBitors). Being COX-2 selective means that these drugs act specifically on one form of the cyclooxygenase (COX) enzyme, namely the COX-2, whereas previous NSAIDs inhibited both COX-1 and COX-2. This specificity allows rofecoxib and other COX-2 inhibitors to reduce inflammation and pain while minimizing undesired gastrointestinal adverse effects - peptic ulcers - that are common with non-selective NSAIDs such as aspirin, naproxen, and ibuprofen.

Interestingly, at the time of its withdrawal, rofecoxib was the only coxib with clinical evidence of its superior gastrointestinal adverse effect profile over conventional NSAIDs. This was largely based on the VIGOR (Vioxx GI Outcomes Research) study, which compared the efficacy and adverse effect profiles of rofecoxib and naproxen. (Bombardier et al., 2000).

Adverse drug reactions

Aside from the reduced incidence of gastric ulceration, rofecoxib exhibits a similar adverse effect profile to other NSAIDs.

Withdrawal from the market

VIGOR study

The VIGOR study, published in 2000, had indicated a significant 4-fold increased risk of acute myocardial infarction (heart attack) in rofecoxib patients when compared with naproxen patients (0.4% vs 0.1%, RR 0.25) over the 12 month span of the study. There was no significant difference in the mortality from cardiovascular events between the two groups. Nor was there any significant difference in the rate of myocardial infarction between the rofecoxib and naproxen treatment groups in patients without high cardiovascular risk. The difference in overall risk was accounted for by the patients meeting the criteria for low-dose aspirin prophylaxis of secondary cardiovascular events (previous myocardial infarction, angina, cerebrovascular accident, transient ischemic attack, or coronary bypass), but who were excluded from taking low-dose aspirin in the initial design study. Once this risk was noted, Merck notified investigators in other rofecoxib studies to modify allow high-risk patients to take low-dose aspirin. (Bombardier et al., 2000)

Merck's scientists interpreted the finding as a protective effect of naproxen in reducing the risk of MI in high cardiovascular risk patients by 80 percent (which some commentators have noted would make naproxen three times as effective as aspirin). The results of the VIGOR study were submitted to the United States Food and Drug Administration (FDA) in February 2001, which led to the introduction, in April 2002, of warnings on Vioxx labelling concerning the increased risk of cardiovascular events (heart attack and stroke).

Read more at Wikipedia.org


[List your site here Free!]


Vioxx dust-up makes for OTC opening
From Drug Store News, 3/7/05 by Michael Johnsen

There currently is scant evidence that the withdrawal of the cox-2 inhibitor Vioxx and subsequent cox-2 controversy has pushed arthritis sufferers over-the-counter in search of safer medicines, but that doesn't mean the opportunity isn't there.

One consequence from all the attention paid to the safety of cox-2 inhibitors and non-steroidal anti-inflammatory drugs as a class of pain relievers may be to drive physicians back to a step-therapy approach to treating osteoarthritis--starting with an analgesic with a low-risk profile, such as acetaminophen, for instance.

Indeed, even though such NSAIDs as ibuprofen and naproxen were associated with an increase in gastrointestinal complications, those remedies were an option at one time as a first line of treatment for arthritis pain. Cox-2 inhibitors were seen as an improvement on that regimen because drugs like Vioxx, Celebrex and Bextra do not carry the same concern over the stomach problem complications associated with the chronic use of NSAIDs.

"The typical patient with osteoarthritis makes that diagnosis before [he consults his family practitioner], commented Dr. Bill McCarberg, founder of Kaiser Permanente's chronic pain management program. "They'll have started glucosamine because they've read about it in Ladies Home Journal," he said. They will have tried Tylenol, Aleve or Advil and are looking to their doctors for a possibly more effective prescription remedy--prescription-strength Mobic, for example, or a cox-2 inhibitor.

Even so, doctors on the front line of osteoarthritis may revert to an NSAID-first approach toward pain management, possibly supplementing that regimen with a proton-pump inhibitor or H-2 blocker to take care of any gastrointestinal discomfort. And that places the first line of treatment for osteoarthritis squarely in OTC aisles.

Already, there has been evidence of an increase in the sale of internal analgesic tablets like Bayer's Aleve (naproxen) and McNeil's Tylenol (acetaminophen). For the 12 weeks ended Dec. 26, sales of Aleve grew 5.4 percent, reaching $37.1 million in food, drug and mass (minus Wal-Mart), while Tylenol Arthritis sales increased 19.8 percent to $14.2 million, according to Information Resources Inc.

And homeopathic supplier GelStat has stepped up its plans to launch GelStat Arthritis, which is expected to launch next month. "Clearly, with what's happening in the marketplace, there's increased demand for safe OTC solutions for people with arthritic pain. That has accelerated our efforts to get the product to market," commented Richard Ringold, GelStat vice president.

Another opportunity that exists along the front end of drug stores can be found in the dietary supplement aisle. The cox-2 controversy may breathe new life into sales of glucosamine and chondroitin products, which have been flagging, even in the wake of the Vioxx withdrawal, according to IRI data.

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group

Return to Vioxx
Home Contact Resources Exchange Links ebay